[go: up one dir, main page]

IN2014MN02539A - - Google Patents

Info

Publication number
IN2014MN02539A
IN2014MN02539A IN2539MUN2014A IN2014MN02539A IN 2014MN02539 A IN2014MN02539 A IN 2014MN02539A IN 2539MUN2014 A IN2539MUN2014 A IN 2539MUN2014A IN 2014MN02539 A IN2014MN02539 A IN 2014MN02539A
Authority
IN
India
Prior art keywords
features
vivo
favorable
analogues
compounds
Prior art date
Application number
Inventor
J L Kiappes
Peter Laing
Raymond Dwek
Nicole Zitzmann
Stephanie Pollock
Original Assignee
Unither Virology Llc
Univ Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unither Virology Llc, Univ Oxford filed Critical Unither Virology Llc
Publication of IN2014MN02539A publication Critical patent/IN2014MN02539A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Iminosugar compounds are described that have inbuilt delivery features by virtue of covalent incorporation of a tocopherol moiety or alternative moieties that are analogues of tocopherol or select analogues of cholesterol or its antagonist 'Ezitimibe'; and are likely to have broad spectrum antiviral activity. The compounds differ from previous iminosugar compounds even lipophillic ones being more hydrophobic and resembling fats and oils in their partition behavior in vivo into lipid phases of lipoproteins cellular lipid droplet organelles and biological membranes. These features confer a number of unique delivery attributes in vivo favorable to the therapy of virus infections involving cells of the lymphoid system and the liver in particular but these features are also favorable in general for the treatment of virus infections of man and animals.
IN2539MUN2014 2012-06-06 2013-06-05 IN2014MN02539A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656265P 2012-06-06 2012-06-06
PCT/US2013/044285 WO2013184780A1 (en) 2012-06-06 2013-06-05 Novel iminosugars and their applications

Publications (1)

Publication Number Publication Date
IN2014MN02539A true IN2014MN02539A (en) 2015-07-24

Family

ID=49712581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2539MUN2014 IN2014MN02539A (en) 2012-06-06 2013-06-05

Country Status (8)

Country Link
US (1) US8921568B2 (en)
EP (1) EP2858642A4 (en)
JP (1) JP2015518896A (en)
KR (1) KR20150035767A (en)
CN (1) CN104703597A (en)
CA (1) CA2875975A1 (en)
IN (1) IN2014MN02539A (en)
WO (1) WO2013184780A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113425720A (en) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 Application of iminosugar compound in preparation of medicine for resisting SARS-CoV-2 virus

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6011902B2 (en) * 1979-12-27 1985-03-28 日本新薬株式会社 Derivatives of moranoline
DE3007078A1 (en) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen NEW DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT AND IN ANIMAL FOOD
US6177447B1 (en) 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
KR20010033028A (en) 1997-12-11 2001-04-25 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 Inhibition of membrane-associated viral replication
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
CA2319713C (en) 1998-02-12 2012-06-26 G.D. Searle & Co. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
ES2311921T3 (en) 1999-02-12 2009-02-16 United Therapeutics Corporation N- (8,8,8-TRIFLUOROOCTIL) 1-5, -DIDESOXI-1,5-IMINO-D-GLUCITOL TO TREAT INFECTIONS BY HEPATITIS VIRUSES.
HK1046869A1 (en) 1999-08-10 2003-01-30 The Chancellor, Masters And Scholars Of The University Of Oxford Long chain n-alkyl compounds and oxa-derivatives thereof and use as antiviral compositions
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
AU3680501A (en) * 2000-02-11 2001-08-20 Res Dev Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
EP1261339A1 (en) * 2000-02-14 2002-12-04 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
AU2003302370A1 (en) 2002-09-23 2004-06-18 The Chancellor, Masters And Scholars Of The University Of Oxford Use of iminosugar derivatives to inhibit ion channel activity
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
CN1949977B (en) * 2004-05-04 2010-09-29 翁启惠 Anti-coronavirus compounds
KR100611931B1 (en) 2004-09-02 2006-08-11 강경태 Optically active alkoxyalcohol compound, optically active 1,3-phenylene-bis [4- (4-alkoxy) phenyliminomethyl] benzoate compound derived therefrom and method for preparing the same
MX2007012253A (en) 2005-04-04 2007-12-07 Univ Pontificia Catolica Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones.
CN104876855A (en) 2006-05-24 2015-09-02 联合治疗公司 Deoxynojirimycin And D-arabinitol Analogs And Methods Of Using
KR20090040906A (en) 2006-08-02 2009-04-27 유나이티드 세러퓨틱스 코오포레이션 Liposomal Treatment of Viral Infections
CA2719567A1 (en) 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
US9040488B2 (en) 2008-09-02 2015-05-26 Baruch S. Blumberg Institute Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
CN106420740A (en) 2009-02-23 2017-02-22 伊莫根特病毒学有限责任公司 Iminosugars and methods of treating viral diseases
KR20170117614A (en) 2009-02-24 2017-10-23 유나이티드 세러퓨틱스 코오포레이션 Iminosugars and methods of treating arenaviral infections
EP2410989A2 (en) 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
CA2765086C (en) 2009-06-12 2015-12-15 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
CA2772875A1 (en) 2009-09-04 2011-03-10 United Therapeutics Corporation Methods of treating orthomyxoviral infections
US20110065753A1 (en) 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating poxviral infections
CN102595895A (en) 2009-09-04 2012-07-18 联合治疗公司 Imino sugars and methods of treating filoviral diseases
WO2011070407A1 (en) 2009-12-07 2011-06-16 University Of Oxford N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation

Also Published As

Publication number Publication date
US8921568B2 (en) 2014-12-30
CN104703597A (en) 2015-06-10
EP2858642A4 (en) 2015-12-02
KR20150035767A (en) 2015-04-07
JP2015518896A (en) 2015-07-06
EP2858642A1 (en) 2015-04-15
CA2875975A1 (en) 2013-12-12
US20130331578A1 (en) 2013-12-12
WO2013184780A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
EA201591662A1 (en) LIPIDS AND LIPID COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS
MX392812B (en) CATIONIC TRIALKYL LIPIDS AND METHODS OF USING THEM.
CR20130617A (en) DERIVATIVES OF PIRIDIN-2 (1H) -ONE USEFUL AS MEDICINES FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, REJECTION OF TRANSPLANTS, DISEASES MEDIATED BY THE IMMUNE SYSTEM AND INFLAMMATORY DISEASES
EA201590693A1 (en) INHIBITORS GDF-8
PH12015501074A1 (en) Triazolopyrazine
FR2986002A1 (en) NOVEL INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PH12015501385A1 (en) Autotaxin inhibitors
MX341332B (en) Biodegradable lipids for the delivery of active agents.
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
IN2014DN00277A (en)
EA201492112A1 (en) SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO [1,2-a] PYRAZIN-1,6-DIONE DERIVATIVES APPLICABLE FOR THE TREATMENT (IN THAT NUMBER) ALZGEYMER
TW200736234A (en) Chemical compounds
PH12013500152A1 (en) New aminopyrazoloquinazolines
EA201791727A1 (en) 7-BENZYL-4- (2-METHYLBENZIL) -2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A] PYRIDO [3,4-E] PYRIMIDIN-5 (1H) -OH, ITS ANALOGUES AND SALTS AND METHODS OF THEIR APPLICATION IN THERAPY
NI201500013A (en) TREATMENT OF IMMUNE - RELATED AND INFLAMMATORY DISEASES.
FR2977486B1 (en) COSMETIC COMPOSITIONS IN THE FORM OF WATER-IN-OIL EMULSIONS COMPRISING A JASMONIC ACID DERIVATIVE
EA201391265A1 (en) AMIDES OF INDOLKARBONIC AND BENZIMIDAZOLOSTERN ACIDS AS INSECTICIDES AND ACARICIDES
MX2014002362A (en) Formulations and dosage forms of oxidized phospholipids.
ECSP099382A (en) HETEROCYCLIC SULFONAMIDS THAT HAVE EDG-I ANTAGONIST ACTIVITY
EP3133073A3 (en) Inhibitors of iap
RU2016109986A (en) COMPOSITION FOR THE SUPPRESSION OF CANCER BLOOD DISEASES OR METASTASIS OF CANCER CONTAINING AS AN ACTIVE INGREDIENT OF MONOACETYL DIGLYCERIDE COMPOUND
IN2014DN01619A (en)
HK1216504A1 (en) Method for treatment of diseases
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
IN2014MN02539A (en)